Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on November 3, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market. The filing serves as a Regulation FD disclosure to disseminate a corporate presentation regarding the company and its product candidates to investors and analysts.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary event is the release of a corporate presentation dated November 3, 2022, which is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing incorporates a corporate presentation by reference but explicitly states that the information is "furnished" and not "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the content is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The filing notes that this information shall not be incorporated by reference into any other SEC filings made by the company.
Key Facts for Investor Verification
- The filing is a Regulation FD disclosure intended to share a corporate presentation with the market.
- Specific financial data is not included in this 8-K; investors must refer to the attached Exhibit 99.1 or other periodic reports for financial details.
- The information provided is furnished and not deemed filed, limiting its legal incorporation into future filings.
- The presentation was authorized by Sabrina Martucci Johnson, President and Chief Executive Officer.